Effects of some pharmacological agents on the survival of unipedicled venous flaps: An experimental study

Basit Öğe Kaydı
dc.authorscopusid56631773100
dc.authorscopusid7004046454
dc.authorscopusid7005744078
dc.authorscopusid6602101658
dc.authorscopusid6508312358
dc.contributor.authorAskar I.
dc.contributor.authorSaray A.
dc.contributor.authorGurlek A.
dc.contributor.authorSevin K.
dc.contributor.authorSabuncuoglu B.T.
dc.date.accessioned2024-08-04T19:59:31Z
dc.date.available2024-08-04T19:59:31Z
dc.date.issued2001
dc.departmentİnönü Üniversitesien_US
dc.description.abstractClinical and experimental studies have been conducted to improve the survival of venous flaps. As a result of these studies, although various survival mechanisms were raised, none obtained satisfactory information. Venous stasis, and the resultant venous thrombosis, is a factor that decreases the survival of venous flaps. In this study, we evaluated the effects of two antiinflammatory agents, etodolac and etofenamate, on the survival of unipedicled venous flaps. In this study, 35 male New Zealand white rabbits (3,500-4,000 g) (70 ears) were used. Perichondrocutaneous flaps, 3 × 4.5 cm in size, were designed and raised, keeping the central veins intact in the middle of venous flap. Central arteries and nerves were ligated and transected both proximally and distally, to prepare unipedicled venous flaps. A silicone sheet was placed between the cartilage tissue and flap, to prevent blood flow and revascularization beneath. The subjects were divided into seven groups, consisting of five rabbits (10 ears). In the negative control group (group I), the single vascular pedicle of venous flaps, central veins were ligated and flaps sutured into their own place as the composite graft. In the positive control group (group II), after venous flaps were prepared, normal saline, 0.2 mL, was given subcutaneously. In the first of five experimental groups (group III), unfractionated heparin (100 U/day) was given subcutaneously. In the second experimental group (group IV), etodolac (5 mg/kg/day) was given subcutaneously. In the third experimental group (group V), etophenamate (5 mg/kg/day) was given orally through a feeding tube. In the fourth experimental group (group VI), parnaparin (5 anti-Xa U/kg/day) was given subcutaneously. In the fifth experimental group (group VII), nadroparin (5 anti-Xa U/kg/day) was given subcutaneously, about 7 days postoperatively. At the eighth postoperative day, surviving areas of venous flaps were measured, and the results were evaluated by Kruskal-Wallis ANOVA and MannWhitney U-test (P < 0.05). Biopsies were also taken from the flaps for histological evaluation of border of necrotic tissue. Surviving areas of unipedicled venous flaps were larger in experimental groups than those in negative and positive control group (P < 0.05). However, comparison of the experimental groups demonstrated no statistically significant dierence (P > 0.05). We concluded that all pharmacological agents used in the experimental groups succeeded in increasing the survival of unipedicled venous flaps. Survival of the unipedicled venous flap was higher in venous flaps than that of composite graft, clearly showing the importance of the venous pedicle. © 2001 Wiley-Liss Inc.en_US
dc.identifier.doi10.1002/micr.21801
dc.identifier.endpage356en_US
dc.identifier.issn0738-1085
dc.identifier.issue8en_US
dc.identifier.pmid11757060en_US
dc.identifier.scopus2-s2.0-0035671542en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage350en_US
dc.identifier.urihttps://doi.org/10.1002/micr.21801
dc.identifier.urihttps://hdl.handle.net/11616/90694
dc.identifier.volume21en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofMicrosurgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectedolaren_US
dc.subjectetodolacen_US
dc.subjectetofenamateen_US
dc.subjectheparinen_US
dc.subjectliquemineen_US
dc.subjectnadroparinen_US
dc.subjectparnaparinen_US
dc.subjectanimal experimenten_US
dc.subjectanimal modelen_US
dc.subjectanimal tissueen_US
dc.subjectarticleen_US
dc.subjectbiopsyen_US
dc.subjectcomposite graften_US
dc.subjectcontrolled studyen_US
dc.subjectgraft survivalen_US
dc.subjectnonhumanen_US
dc.subjectpedicled skin flapen_US
dc.subjectpriority journalen_US
dc.subjectrabbiten_US
dc.subjectrevascularizationen_US
dc.subjectvein graften_US
dc.subjectvein thrombosisen_US
dc.subjectvenous flapen_US
dc.subjectvenous stasisen_US
dc.subjectAnimalsen_US
dc.subjectAnti-Inflammatory Agents, Non-Steroidalen_US
dc.subjectEtodolacen_US
dc.subjectFlufenamic Aciden_US
dc.subjectGraft Survivalen_US
dc.subjectMaleen_US
dc.subjectRabbitsen_US
dc.subjectSurgical Flapsen_US
dc.titleEffects of some pharmacological agents on the survival of unipedicled venous flaps: An experimental studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu